41 results on '"Cesne, Axel Le"'
Search Results
2. Zolbetuximab: a potential breakthrough in the treatment landscape of gastric cancer
3. Ipilimumab and nivolumab: the ‘new kid on the block’ in advanced angiosarcoma
4. Trabectedin and radiotherapy in soft tissue sarcomas: friends or foes?
5. LAG-3 Inhibitors: Novel Immune Checkpoint Inhibitors Changing the Landscape of Immunotherapy
6. NALIRIFOX in the upfront setting of metastatic pancreatic cancer: can FOLFIRINOX finally be dethroned?
7. Traitement par imatinib des tumeurs stromales gastro-intestinales, 20 ans après*
8. KRAS G12C mutation: from black sheep to key player in pancreatic cancer treatment
9. Management and outcomes of adolescent and young adult sarcoma patients: results from the French nationwide database NETSARC
10. Trabectedin and immune checkpoint inhibitors: a blissful combination or another failure in soft tissue sarcomas?
11. Final Safety and Health-Related Quality of LIfe Results of the Phase 2/3 Act.In.Sarc Study With Preoperative NBTXR3 Plus Radiation Therapy Versus Radiation Therapy in Locally Advanced Soft-Tissue Sarcoma
12. A novel fusion variantLSM14A :: NR4A3in extraskeletal myxoid chondrosarcoma
13. Single‐agent gemcitabine in patients with advanced, pre‐treated angiosarcoma: A multicenter, retrospective study
14. Management and Outcomes of Pediatric, Adolescent and Young Adult Sarcoma Patients: Results from the French Nationwide Database NETSARC
15. Systemic Treatment in Advanced Phyllodes Tumor of the Breast: A Multi-Institutional European Retrospective Case-Series Analyses
16. Systemic Treatment in Advanced Phyllodes Tumor of the Breast: A Multi-institutional European Retrospective Case-series Analyses
17. Metastatic risk stratification of leiomyosarcoma patients using transcription- and replication-associated chromosomal instability mechanisms
18. Is there a role for immune checkpoint inhibitors in selected rare subtypes of soft tissue sarcoma?
19. Pregnancy in Women with Metastatic Sarcomas
20. Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network
21. Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses
22. EPIGIST: An observational real-life study on patients with metastatic gastrointestinal stromal tumors receiving imatinib
23. Quality of life and patients’ expectations in soft tissue sarcoma
24. Expression and role of TYRO3 and AXL as potential therapeutical targets in leiomyosarcoma
25. Abstract LB-190: Combination of pembrolizumab and metronomic cyclophosphamide in patients with advanced sarcomas: a french sarcoma group study
26. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial
27. Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial
28. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial
29. Algorithme de prise en charge des tumeurs des tissus mous du périnée
30. Primary pleuropulmonary sarcoma: what we know about it?
31. Efficacy and safety of trabectedin as an early treatment for advanced or metastatic liposarcoma and leiomyosarcoma
32. A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas
33. Phase III, placebo-controlled trial (SUCCEED) evaluating ridaforolimus as maintenance therapy in advanced sarcoma patients following clinical benefit from prior standard cytotoxic chemotherapy: Long-term (≥ 24 months) overall survival results.
34. Effect of five years of imatinib on cure for patients with advanced GIST: Updated survival results from the prospective randomized phase III BFR14 trial.
35. Le traitement médical des GIST : du palliatif au curatif
36. Trends in survival for patients with metastatic soft-tissue sarcoma
37. Abstract 1780: p53 mutation predicts limited benefit from adjuvant chemotherapy in patients with localized completely resected high grade soft tissue sarcoma: a retrospective study on 117 patients of the French Sarcoma Group
38. Adjuvant treatment of GIST with imatinib: Solid ground or still quicksand? A comment on behalf of the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group, the NCRI Sarcoma Clinical Studies Group (UK), the Japanese Study Group on GIST, the French Sarcoma Group and the Spanish Sarcoma Group (GEIS)
39. Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: A study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC–ISG–AGITG)
40. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell–dependent antitumor effects
41. Surgery for pulmonary metastases. Who are the 10-year sruviors?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.